Bryce Point Capital LLC Sells 6,528 Shares of Natera, Inc. (NASDAQ:NTRA)

Key Points

• Bryce Point Capital LLC reduced its stake in Natera, Inc. by 54.7%, now holding 5,411 shares valued at $834,000 at the end of the last quarter.
• Natera reported a quarterly revenue of $501.83 million, exceeding consensus estimates and reflecting a 36.5% year-over-year growth.
• Despite recent insider stock sales, analysts remain optimistic, with an average rating of "Moderate Buy" and a target price of $184.63 for Natera shares.

Bryce Point Capital LLC reduced its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 54.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,411 shares of the medical research company's stock after selling 6,528 shares during the quarter. Bryce Point Capital LLC's holdings in Natera were worth $834,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. LRI Investments LLC bought a new position in shares of Natera during the 4th quarter worth approximately $29,000. Rakuten Securities Inc. boosted its stake in Natera by 117.8% in the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after purchasing an additional 119 shares during the period. ORG Partners LLC bought a new stake in Natera in the 1st quarter valued at $32,000. ANTIPODES PARTNERS Ltd bought a new stake in Natera in the 1st quarter valued at $40,000. Finally, Covestor Ltd boosted its stake in Natera by 42.7% in the 4th quarter. Covestor Ltd now owns 531 shares of the medical research company's stock valued at $84,000 after purchasing an additional 159 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CEO Steven Leonard Chapman sold 6,092 shares of the stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $139.81, for a total value of $851,722.52. Following the completion of the sale, the chief executive officer owned 169,400 shares of the company's stock, valued at approximately $23,683,814. This represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider John Fesko sold 1,710 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $139.81, for a total value of $239,075.10. Following the completion of the sale, the insider directly owned 151,750 shares of the company's stock, valued at approximately $21,216,167.50. The trade was a 1.11% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 48,936 shares of company stock worth $7,483,846. Corporate insiders own 7.60% of the company's stock.

Natera Trading Down 4.1%

NTRA traded down $5.72 on Thursday, reaching $135.24. The stock had a trading volume of 742,506 shares, compared to its average volume of 1,489,707. Natera, Inc. has a fifty-two week low of $92.14 and a fifty-two week high of $183.00. The firm has a 50-day moving average of $158.12 and a 200-day moving average of $156.45. The company has a market capitalization of $18.47 billion, a price-to-earnings ratio of -92.36 and a beta of 1.73.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The business had revenue of $501.83 million during the quarter, compared to analysts' expectations of $446.68 million. During the same quarter in the prior year, the firm earned ($0.56) EPS. The business's revenue for the quarter was up 36.5% compared to the same quarter last year. Sell-side analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NTRA has been the subject of several recent research reports. Barclays boosted their price target on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. UBS Group lifted their price objective on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a report on Friday, May 9th. Wall Street Zen cut Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Evercore ISI raised Natera to a "strong-buy" rating and set a $170.00 price objective for the company in a report on Monday. Finally, Piper Sandler lifted their price objective on Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Natera currently has an average rating of "Moderate Buy" and a consensus target price of $183.76.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.